Effectiveness and safety of oral terbinafine for dermatophyte distal subungual onychomycosis

Gupta, Aditya K.; Polla Ravi, Shruthi; Talukder, Mesbah; Mann, Avantika

doi:10.1080/14656566.2024.2305304

Expert Opinion on Pharmacotherapy

2024

DOI: 10.1080/14656566.2024.2305304

|View full text |Cite

Effectiveness and safety of oral terbinafine for dermatophyte distal subungual onychomycosis

Aditya K. Gupta,

Shruthi Polla Ravi,

Mesbah Talukder

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions

Shawky,

Almalki,

Alzahrani

et al. 2024

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions

Shawky,

Almalki,

Alzahrani

et al. 2024

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

Safety and efficacy of new generation azole antifungals in the management of recalcitrant superficial fungal infections and onychomycosis

Gupta,

Talukder,

Shemer

et al. 2024

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Systemic absorption and safety of topical terbinafine hydrochloride 10% solution (MOB015B): a phase 1 maximal usage trial in patients with moderate-to-severe onychomycosis

Tavakkol,

DuBois,

Gupta

2024

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Topical antifungals may be considered to treat onychomycosis with minimal risk of systemic side effects. In this study, we assess the safety, tolerability, systemic exposure, and pharmacokinetic characteristics of topical terbinafine hydrochloride 10% solution (MOB015B) in adults with moderate-to-severe onychomycosis. Clinically and mycologically confirmed patients with toenail onychomycosis ( N = 20) were enrolled in this single-center, open-label study . Each patient had ≥50% involvement of both great toenails and at least four additional toenails affected. MOB015B was applied once daily to all toenails for 28 days. Blood was drawn on days 1, 14, and 28. Plasma concentrations of MOB015B after the first dose were quantifiable in all subjects by 24 h. Steady-state levels in plasma were reached by day 28. The mean systemic exposure on day 28 of 0.72 ng/mL for maximum plasma concentration (C max ) was approximately 2,000 times lower than the mean plasma level of 1.39 µg/mL seen after oral administration of 250 mg terbinafine for 28 days. Adverse events (five patients), such as headache ( n = 3), seasonal allergy ( n = 1), and neck pain ( n = 1), were considered unrelated to MOB015B; no application site reactions or study discontinuations due to an adverse event were observed. MOB015B applied to all affected toenails under maximal usage conditions for 28 days demonstrated very low levels of terbinafine in plasma (C max <1 ng/mL after 28 days), consistent with a favorable safety and tolerability profile. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT03244280 .

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Effectiveness and safety of oral terbinafine for dermatophyte distal subungual onychomycosis

Cited by 5 publications

References 64 publications

Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions

Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions

Safety and efficacy of new generation azole antifungals in the management of recalcitrant superficial fungal infections and onychomycosis

Systemic absorption and safety of topical terbinafine hydrochloride 10% solution (MOB015B): a phase 1 maximal usage trial in patients with moderate-to-severe onychomycosis

Contact Info

Product

Resources

About